Amal Trivedi, MD, MPH, professor at Brown University, discusses the qualities that led him to nominate David J. Meyers, PhD, to receive the Seema S. Sonnad Emerging Leader in Managed Care Research Award. The American Journal of Managed Care® presented the award to Dr Meyers at the 2023 Patient-Centered Oncology Care® meeting.
Amal Trivedi, MD, MPH, professor at Brown University, discusses the qualities that led him to nominate David J. Meyers, PhD, to receive the Seema S. Sonnad Emerging Leader in Managed Care Research Award. The American Journal of Managed Care presented the award to Dr Meyers at the 2023 Patient-Centered Oncology Care meeting.
Transcript
My name is Amal Trivedi and I’m a faculty member in Brown University’s School of Public Health, and I am delighted to congratulate David Meyers on his receipt of The American Journal of Managed Care’s Seema Sonnad Emerging Leader in Managed Care Research Award. I also want to thank the selection committee for acknowledging David's contributions to the field, and also to Andy Ryan for jointly nominating David with me.
In a remarkably short time, David Meyers has become a recognized leader in managed care research, and in particular in policy related to Medicare Advantage and payment reform. There are a number of important themes that distinguish David's contributions and I want to briefly highlight 3 here.
First, one of the key foundations of David's work is a focus on equity.
David has published seminal studies that enhance our understanding of disparities in the quality of care in the Medicare Advantage program, and his work has really also identified features of plans that are connected not only to better overall performance but also more equitable care. As another example, David is leading highly innovative work related to understanding and reducing transgender health disparities in the Medicare program.
The second aspect of David's work that I want to highlight is that it has direct, actionable, and often immediate implications for policy. David's research has informed congressional legislation, issue briefs from Senate offices, reports from the General Accounting Office, as well as MedPAC, and he's often been sought out to provide expert guidance to leaders in the Medicare program. In short, David's work is attracting policy interest and it's making a difference.
And finally, David is a prolific mentor. He is a kind and generous advisor for students and trainees, many of whom come from backgrounds that are underrepresented in our field. So David is having a huge impact on the future of health services research, and it's really an honor to be his colleague and friend. So again, congratulations, David, and thank you to the committee for selecting him for this prestigious award in honor of Dr Sonnad’s legacy.
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen